Arcutis Biotherapeutics, Inc.
NASDAQArcutis Biotherapeutics enters its Q2 2026 earnings call — confirmed for June 5 — with short interest running at a 30-day high and the stock down 11% over the past month, creating a pointed test of the bull thesis around Zoryve's commercial trajectory. Short sellers have quietly added pressure over the past four weeks. Short interest has climbed to 14.3% of the free float — up…
Snapshot as of 22 Jun 2026
Arcutis Biotherapeutics enters its Q2 2026 earnings call — confirmed for June 5 — with short interest running at a 30-day high and the stock down 11% over the past month, creating a pointed test of the bull thesis…
Arcutis Biotherapeutics filed Q1 2026 results after the close on May 6, delivering a split verdict that puts the stock's 13.5% short interest in an interesting position heading into the next trading session. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARQT — free to start on ORTEX.
Sign up for free →Open ARQT on ORTEX